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INTRODUCTION
The Clinical Trials Network (CTN) of
the National Institute on Drug Abuse
(NIDA) recently launched a public por-
tal (http://cde.drugabuse.gov) (1), which
provides a single-source repository for
CTN-recommended common data ele-
ments (CDEs) for substance use disorders
(SUD) for use in electronic health record
systems (EHRs) and clinical research (1,
2). A CDE in this context is a data ele-
ment consisting of a question and enumer-
ated set of possible values for responses
precisely defined by standardized meta-
data descriptors (1). CDEs consisting of
individual question/answer pairs can be
combined into more complex question-
naires and case report forms or used when
gathering medical information in the con-
text of providing clinical care (1). Thus,
CDEs describe semantic characteristics for
a discrete piece of data, which will be col-
lected, stored, or exchanged during the
course of a study or health examination.
This will facilitate exchange of standard-
ized data because of the use of CDEs (1).
In this manner, NIDA CDEs can be com-
monly applied to multiple data collection
systems whether in research or clinical care
and across different institutions, such that
their intentional commonality with use of
common data standards can improve data
quality, facilitate data re-purposing, and
promote data sharing (1, 2). This paper
describes objectives and importance of the
CTN CDEs initiative and portal to trans-
lational psychiatric research: To support
harmonized use of EHR-compatible com-
mon data elements to enable exchange
and integration of data to answer clinically
meaningful questions of broad interest to
SUD treatment research, thereby facilitat-
ing big-data biomedical science crossing
boundaries between research and clinical
care.
APPROACH
Over a series of consensus-building meet-
ings from 2010 to the present, the CTN
has led a coordinated effort involving
many United States (U.S.) federal govern-
ment and state agencies, provider organi-
zations, academic institutions, and profes-
sional societies to develop CDEs of SUD
domains for both EHRs and SUD clini-
cal research (2, 3). The objective of this
NIDA-led initiative is to establish measure
commonality for SUD care and research
that could be integrated into primary care
practices in general medical settings, by
facilitating the uniform use of EHR-based
CDEs (2, 3).
The CTN CDE portal (1) encourages
human-subjects research investigators to
use, as applicable to their research, a
concise set of CDEs when developing
case report forms. To ensure meaningful
exchange and compatibility of data ele-
ments across EHRs and other data manage-
ment systems, NIDA-recommended CDEs
have been developed and curated accord-
ing to a well-established Metadata Reg-
istry standard and archived in the National
Cancer Institute’s (NCI) Cancer Data Stan-
dards Registry and Repository (caDSR)
(1). Definitions and annotations for the
NIDA CTN CDEs originate with the
NCI Enterprise Vocabulary Service (EVS),
which contains standardized terminolo-
gies enabling semantic interoperability and
health information exchange across EHRs
and other data management systems.
One small subset of CDEs is intended
for use by practitioners in EHRs of general
medical settings,and categorized separately
for ease of access (1, 2). EHR vendors are
strongly encouraged to select SUD-relevant
data elements for their systems from this
list, and thus disseminate use of a core set
of common standards (2). Additional stan-
dardized CDEs are principally intended for
clinical research on SUD and co-occurring
conditions (e.g., chronic pain, depression),
and may also be considered for EHRs for
specific purposes (1).
A lack of measure commonality has
frequently been encountered in different
areas and scientific domains of substance
abuse and addiction (SAA) research (4). To
address this absence of measure common-
ality, NIDA strongly encourages NIDA-
supported human-subjects research inves-
tigators to use Core Tier-1 measures of the
SAA project of the phenotypes and expo-
sures (PhenX) Toolkit, as referenced on
the NIDA CDE portal. This is a means
to facilitate cross-study comparisons and
combined data analyses needed to vali-
date and extend human-subjects research
results (4). Thus, consistent with NIDA’s
efforts to increase measure commonal-
ity and establish common data standards
across human-subjects research, many of
the CTN CDEs in the CTN CDE portal are
mapped via CDE entries in the caDSR to
Core Tier-1 domains and measures of the
SAA PhenX Toolkit (1).
All CTN CDEs are based on a well-
established common data standard –
the ISO/IEC 11179 metadata registry
standard – thus providing semantic inter-
operability for potential data exchange (1,
2). These CDEs are intended to support
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useful research using comparative big-
data analyses crossing boundaries between
human-subjects research and clinical care
in large healthcare systems. These are a
means by which NIDA advances the U.S.
Institute of Medicine’s (IOM’s) vision of a
“learning health care system,”in which clin-
ical research could be readily transportable
and translatable to practical point-of-care
applications at large healthcare system set-
tings and psychiatric practices (5). In addi-
tion, integrating CDEs with actionable
clinical decision support tools into EHRs
of general medical settings may strengthen
links between behavioral medicine and pri-
mary care in the context of new health
reform delivery models, such as Patient-
Centered Medical Homes, Accountable
Care Organizations, and Coordinated Care
Organizations by facilitating standardized
systematic data collection, health infor-
mation exchange, and outcome report-
ing in these integrated health care sys-
tems. Strengthening of care coordination
through harmonized data collection and
exchange is consistent with one of the pil-
lars of the U.S. Department of Health and
Human Services strategic plan on treat-
ment of Multiple Chronic Conditions and
for improved quality of patient-centered
care (6). It also supports several key attrib-
utes defined by the IOM as needed in EHRs
functionalities of primary care practices
to longitudinally track and provide quality
patient-centered care, such as adoption of
standardized vocabularies and coding sys-
tems (e.g., CDEs) to enable uniform meth-
ods for collecting and monitoring patient
health information (7).
With increased capacity to share data,
safeguarding privacy remains a foremost
concern for behavioral health patients and
their providers. Title 42, Part 2, of the
U.S. Code of Federal Regulations (42 CFR
Part 2) is a statute concerning the sharing
of substance use information from spe-
cific providers. SUD clinical researchers
and providers need to safeguard patient
privacy in accordance with the confiden-
tiality provisions afforded by 42 CFR Part
2, in addition to those of the Health
Insurance Portability and Accountability
Act (HIPAA). In addition, in U.S. states
where clinical information is collected,
there need to be state-wide confidential-
ity and security regulations and measures
in place to specify how protected health
information (PHI) data may be accessed,
extracted, queried, and analyzed. Further-
more, patients included in clinical research
using CDEs need to provide informed con-
sents approved by applicable institutional
review boards (IRBs). Also, when clinical-
research data are reused, they should be in
an aggregated format, and PHI should be
excluded to minimize risks of disclosing
identities of patients. Previous commen-
taries have discussed the processes by which
meaningful use of EHRs is able to address
these considerations and process informed
consents and data sharing in accordance
with such privacy standards (3, 8).
CLINICAL IMPLICATIONS, NEW
DIRECTIONS, AND CONCLUSION
In sum, NIDA has established expert-
defined and consensus-based CDEs (1,
2) housed in the CTN CDE portal (1),
which clinical-research investigators and
EHR vendors are encouraged to use. Wide-
spread use of these CDEs can acceler-
ate efficient start-up and conduct of new
clinical-research projects by providing a set
of established data elements from which
investigators can select. The vision of the
CTN CDEs initiative is to improve qual-
ity of data collection in clinical care and
biomedical research by fostering standard-
ized utilization of data collection tools that
have been validated or vetted by expert
groups in the scientific community. Har-
monized data collection through use of
CTN CDEs can improve big-data biomed-
ical science by facilitating comparison of
results across research studies and enable
aggregated analyses of data from multiple
studies to provide new insight and greater
statistical power to answer clinically mean-
ingful questions (2). Through a continued
partnership with U.S. federal, state agency,
academic institution, provider organiza-
tion, and professional society stakeholders
in updating the CTN CDEs as the sci-
ence evolves and encouraging their broad
use in clinical research and care, NIDA
plans to advance biomedical big data accel-
erating translation of promising research
into practical knowledge in a “Learning
Health Care system” (5). CDEs cross-
ing boundaries between clinical research
and care – such as NIDA CTN CDEs
pertinent to clinical researchers, clinicians,
and EHR vendors – can help facilitate data
integration and reusability across EHRs
and clinical data management systems.
Thus, they enable transportability of clin-
ical research to healthcare system settings
within a “Learning Health Care System”
(1, 2, 5).
In order to advance such a sys-
tem through U.S. Centers for Medicare
and Medicaid Services (CMS) quality-
improvement reporting and reimburse-
ment programs (9), systematic integration
of SUD care into medical settings is needed
whereby persons seeking primary care are
routinely screened for harmful substance
use through validated EHR-based assess-
ment tools (2, 3, 10–12). Importantly, if
physicians in general medical settings do
not have incentives to screen for harm-
ful drug use and intervene appropriately –
guided by pertinent clinical quality mea-
sures (CQMs) in EHRs – SUDs would likely
go undetected or under-detected in pri-
mary care and confound patient-centered
care (13). One potential step to promote
integration of SUD care with other medical
care is inclusion of an EHR-based CQM rel-
evant to substance use screening and inter-
vention for primary-care professionals in
CMS-reimbursement programs. Develop-
ment of an evidence-based CQM reporting
on systematic screening, and correspond-
ing interventions, for medically harmful
substance use could be used to provide
standardized terminology and electronic
specification for the uniform collection and
exchange of clinically relevant health infor-
mation in EHRs of integrated healthcare
systems. This healthcare delivery integra-
tion would in turn help support healthcare
program evaluations/quality improvement
for treating patients with SUD and chronic
co-occurring conditions (13).
To facilitate adoption of validated
screening and intervention for SUD in pri-
mary care settings – in order to advance
systematic collection of biomedical big data
in a “Learning Health Care System” cross-
ing boundaries between clinical research
and preventive care – the CTN has sup-
ported development and electronic spec-
ification of an evidence-based composite
measure for screening and intervention for
substance use (13). The composite CQM is
entitled“Substance use screening and inter-
vention composite.” The American Soci-
ety of Addiction Medicine is the mea-
sure steward. Since many patients who are
at risk for SUD have not yet developed
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detectable problems associated with sub-
stance use, screening can identify high-
risk patients for whom intervention can be
indicated. This CQM is defined as the per-
centage of patients aged 18 years and older
who were screened at least once within the
last 24 months for tobacco use, unhealthy
alcohol use, non-medical prescription drug
use, and illicit drug use AND who received
an intervention for all positive screening
results. Thus, this CQM is intended to
evaluate the extent to which primary care
patients receive evidence-based screenings
for potential abuse of several categories
of substances, including tobacco, alco-
hol, and other drugs, and to encourage
comprehensive screening and accompany-
ing intervention (13). A composite CQM
was developed to make provider assess-
ments comprehensive. The information
in this composite CQM is highly con-
densed, allowing for the efficient tracking
and reporting of a broad range of perfor-
mance metrics relevant to substance use
and abuse. The CTN has provided finan-
cial support and oversight for the develop-
ment and e-specification of this composite
CQM with the aim of completing testing of
this measure for potential inclusion among
CQMs required for eligible professionals in
primary care settings to report to obtain
CMS-reimbursement incentives (13).
In summary, promoting use of such a
CQM and the CDEs in the CTN CDE por-
tal is an important means by which CTN
and other stakeholders aim to advance
the uniform collection and pooling of
big-data sets across studies and sources,
including EHRs in general medical set-
tings, to improve data quality and answer
clinically meaningful research questions.
Using the NIDA CDEs and implement-
ing the aforementioned CQM may be a
foundation upon which to develop efficient
pragmatic and patient-centered research
on how to effectively integrate manage-
ment of SUD with primary care in general
medical settings.
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